Caplin Steriles Limited

Caplin Steriles Limited is an Indian pharmaceutical company that serves as the sterile-injectables and regulated-market manufacturing subsidiary of Caplin Point Laboratories Ltd., a Chennai-headquartered drugmaker. The company is associated with the production of sterile dosage forms — principally liquid injectables, lyophilized (freeze-dried) vials, and related sterile pharmaceutical products — for markets that demand stringent regulatory compliance, including the United States and other regulated territories. Caplin Steriles operates as the group's vehicle for moving beyond the emerging-market-focused business of its parent into higher-value, regulated pharmaceutical markets. Its facilities are designed to meet international good-manufacturing-practice standards, and the unit has pursued approvals from agencies such as the U.S. Food and Drug Administration, which is a prerequisite for selling sterile injectables in the United States. The sterile injectables segment is strategically important because it typically carries higher margins and higher barriers to entry than oral solid dosage forms. The company is not separately listed; it is a subsidiary within the Caplin Point Laboratories group, which is publicly traded in India. Its identity is therefore tied closely to its parent's strategy of expanding from semi-regulated markets into the United States and other regulated regions through a dedicated sterile-manufacturing platform. Because the supplied evidence does not contain verifiable information about Caplin Steriles Limited, this dossier relies on well-established public facts about the company and its parent group. Details such as exact founding dates, specific plant locations, product lists, and executive names should be confirmed against the company's official disclosures before being treated as definitive.

Caplin Steriles Limited is the sterile-injectables and regulated-market subsidiary of Caplin Point Laboratories Ltd., an Indian pharmaceutical group headquartered in Chennai, Tamil Nadu. Caplin Point Laboratories was founded in the late 1980s and built its early business around supplying pharmaceutical products to semi-regulated and emerging markets, particularly in Latin America and Africa, where it developed a distribution-led model. As the group matured, it sought to move into higher-value, regulated markets such as the United States, where sterile injectables command higher prices and face significant barriers to entry. Caplin Steriles was established as the dedicated platform for this strategy, focused on the development and manufacture of sterile dosage forms — liquid injectables and lyophilized vials — at facilities designed to meet international regulatory standards. The sterile-injectables unit has pursued approvals from the U.S. Food and Drug Administration and other regulators, which are required to commercialize products in those markets. This regulatory pathway is central to the subsidiary's identity: unlike the parent's traditional emerging-market business, Caplin Steriles is oriented toward compliance-heavy, higher-margin regulated markets. Because the supplied evidence does not contain verifiable information about Caplin Steriles Limited, this history is based on well-established public facts about the company and its parent group. Specific dates, facility details, and product approvals should be verified against official company disclosures.

A regulated-market sterile-injectables manufacturing platform within the Caplin Point Laboratories group.

• Sterile liquid injectables

  Injectable pharmaceutical products in liquid form for regulated markets.

• Lyophilized injectables

  Freeze-dried injectable products requiring reconstitution before use.

• Unconfirmed

  Reported2026.01.01

  Caplin Point acquires 10 approved ANDAs for injectable and ophthalmic products[1]Caplin Point 收购10项注射剂和眼科产品ANDAthehindubusinessline.com

  Caplin Point Laboratories, through subsidiaries Caplin Steriles Limited and Caplin One Labs Limited, acquired 10 approved Abbreviated New Drug Applications for injectable and ophthalmic products from a leading multinational generic product manufacturing company, with an addressable market of $473.2 million for the 12 months ending August 2025.

Read more

1. 1Caplin Point 收购10项注射剂和眼科产品ANDAthehindubusinessline.com